CERO...All out at .38/39...from .21s this morning...🥳
georgie18
Member Level
Re: georgie18 post# 664663
Friday, November 15, 2024 8:47:58 AM
Post#
665102
of 665112
CERO...21s clearing here...Back in on News for a flip...🥳
georgie18
Member Level
Re: georgie18 post# 664663
Friday, November 15, 2024 8:47:58 AM
Post#
665102
of 665112
CERO...21s clearing here...Back in on News for a flip...🥳
Recent CERO News
- CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial • GlobeNewswire Inc. • 03/30/2026 12:15:00 PM
- CERo Therapeutics Provides Shareholder Update • GlobeNewswire Inc. • 03/11/2026 12:15:00 PM
- CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors • GlobeNewswire Inc. • 02/17/2026 01:00:00 PM
- CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient • GlobeNewswire Inc. • 02/04/2026 02:05:00 PM
- CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML • GlobeNewswire Inc. • 01/07/2026 02:09:00 PM
- CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1) • GlobeNewswire Inc. • 12/17/2025 01:00:00 PM
- CERo Therapeutics Announces Trading on OTCQB Market • GlobeNewswire Inc. • 12/02/2025 12:30:00 PM
- CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing • GlobeNewswire Inc. • 11/05/2025 01:00:00 PM
- CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response • GlobeNewswire Inc. • 11/04/2025 02:05:00 PM
- CERo Therapeutics Announces Listing on OTC Markets • GlobeNewswire Inc. • 11/03/2025 01:00:00 PM
- CERo Therapeutics Announces Receipt of Nasdaq Panel Determination • GlobeNewswire Inc. • 10/29/2025 11:22:58 PM
- CERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AML • GlobeNewswire Inc. • 10/21/2025 12:15:00 PM
- CERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025 • GlobeNewswire Inc. • 10/15/2025 12:30:00 PM
- CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML • GlobeNewswire Inc. • 10/13/2025 12:30:00 PM
- CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort • GlobeNewswire Inc. • 09/22/2025 01:15:00 PM
- CERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041 • GlobeNewswire Inc. • 09/09/2025 12:15:00 PM
- CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia • GlobeNewswire Inc. • 09/08/2025 12:45:00 PM
- CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML) • GlobeNewswire Inc. • 09/05/2025 12:00:00 PM
- CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236 • GlobeNewswire Inc. • 07/31/2025 12:10:00 PM
- CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 • GlobeNewswire Inc. • 06/23/2025 12:15:00 PM
- CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML) • GlobeNewswire Inc. • 06/17/2025 12:15:00 PM
- CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split • GlobeNewswire Inc. • 06/11/2025 01:10:00 PM
- CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing • GlobeNewswire Inc. • 06/06/2025 12:15:00 PM
- CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company’s Lead Compound CER-1236 • GlobeNewswire Inc. • 06/02/2025 01:05:00 PM
- CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations • GlobeNewswire Inc. • 05/30/2025 12:15:00 PM
